Boston Therapeutics Inc (BTHE) - OTCQB
  • Nov. 7, 2014, 4:20 PM
    • Boston Therapeutics Inc (OTCQB:BTHE): Q3 EPS of -$0.03 vs. -$0.04 in 3Q13.
    • Revenue of $0.12M (-42.9% Y/Y).
    | Nov. 7, 2014, 4:20 PM
  • Aug. 8, 2014, 11:11 AM
    • Boston Therapeutics (OTCQB:BTHE) Q2 results: $21.4K (+910.0%); Operating Expenses: $1.2M (+137.0%); Operating Loss: ($1.2M) (-133.3%); Net Loss: ($1.2M) (-133.3%); Loss Per Share: ($0.03) (unch); Quick Assets: $1.5M (-55.5%).
    • No financial guidance given.
    | Aug. 8, 2014, 11:11 AM
Company Description
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is a leader in the field of designing drugs using complex carbohydrates. The Company's product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including: BTI-320, a non-systemic chewable... More
Sector: Healthcare
Industry: Biotechnology
Country: United States